{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.5mL+Intramuscular+Injection",
    "query": {
      "intervention": "0.5mL Intramuscular Injection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 51,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.5mL+Intramuscular+Injection&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T13:29:28.456Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02388165",
      "title": "Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcal Vaccine"
      ],
      "interventions": [
        {
          "name": "Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 3450,
      "start_date": "2015-07-02",
      "completion_date": "2019-06-27",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 234,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02388165"
    },
    {
      "nct_id": "NCT05293665",
      "title": "Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19 Vaccines"
      ],
      "interventions": [
        {
          "name": "UB-612",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ChAdOx1-S vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sinopharm BIBP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxxinity, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 944,
      "start_date": "2022-03-16",
      "completion_date": "2023-09",
      "has_results": false,
      "last_update_posted_date": "2022-10-14",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 1,
      "location_summary": "Brownsville, Texas",
      "locations": [
        {
          "city": "Brownsville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05293665"
    },
    {
      "nct_id": "NCT00328107",
      "title": "Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Vaccine, recombinant Hemagglutinin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protein Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 459,
      "start_date": "2004-11",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2010-01-12",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 3,
      "location_summary": "Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00328107"
    },
    {
      "nct_id": "NCT00532792",
      "title": "A/H5N1 Dose Ranging Study With Adjuvant Patch",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pandemic Influenza"
      ],
      "interventions": [
        {
          "name": "A/H5N1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Intercell USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 501,
      "start_date": "2007-08",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2012-03-14",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 5,
      "location_summary": "Vallejo, California • Miami, Florida • Kansas City, Kansas + 2 more",
      "locations": [
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00532792"
    },
    {
      "nct_id": "NCT05238025",
      "title": "MVA-BN-RSV Vaccine Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "MVA-BN-RSV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tris Buffered Saline (TBS)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 20419,
      "start_date": "2022-04-19",
      "completion_date": "2023-09-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 105,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05238025"
    },
    {
      "nct_id": "NCT00806195",
      "title": "Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis",
        "Meningococcal Infection"
      ],
      "interventions": [
        {
          "name": "MenACWY-CRM197",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP (Diptheria, Tetanus, Pertussis) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hib (Haemophilus influenza b) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IPV (Inactivated Polio Vaccine) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR (Measles, Mumps, and Rubella) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A Virus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "55 Days to 89 Days"
      },
      "enrollment_count": 7744,
      "start_date": "2008-12",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2013-07-09",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 130,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00806195"
    },
    {
      "nct_id": "NCT02718469",
      "title": "Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Virus Disease"
      ],
      "interventions": [
        {
          "name": "Ebola Vaccine - low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ebola Vaccine - mid dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ebola Vaccine - high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Auro Vaccines LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 38,
      "start_date": "2015-12-22",
      "completion_date": "2016-09-15",
      "has_results": false,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 1,
      "location_summary": "Melbourne, Florida",
      "locations": [
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02718469"
    },
    {
      "nct_id": "NCT00767897",
      "title": "The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Disease",
        "Dialysis"
      ],
      "interventions": [
        {
          "name": "Human Papillomavirus Vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "9 Years to 18 Years · Female only"
      },
      "enrollment_count": 72,
      "start_date": "2011-11",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2024-03-29",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00767897"
    },
    {
      "nct_id": "NCT00511095",
      "title": "Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "HEPLISAV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "11 Years to 55 Years"
      },
      "enrollment_count": 207,
      "start_date": "2007-06",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2019-04-30",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 7,
      "location_summary": "Boardman, Ohio • Grove City, Pennsylvania • Pittsburgh, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Boardman",
          "state": "Ohio"
        },
        {
          "city": "Grove City",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Upper Saint Clair",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511095"
    },
    {
      "nct_id": "NCT05329961",
      "title": "Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "Gardasil9",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "4 Years to 8 Years"
      },
      "enrollment_count": 155,
      "start_date": "2022-09-26",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-09-03T13:29:28.456Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05329961"
    }
  ]
}